Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares gapped up before the market opened on Thursday after Raymond James raised their price target on the stock from $34.00 to $51.00. The stock had previously closed at $23.34, but opened at $24.36. Raymond James currently has an outperform rating on the stock. Dianthus Therapeutics shares last traded at $23.94, with a volume of 9,679 shares trading hands.

A number of other research firms have also recently issued reports on DNTH. Jefferies Financial Group boosted their price objective on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Wedbush upped their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Finally, Stifel Nicolaus began coverage on Dianthus Therapeutics in a research report on Thursday, February 15th. They issued a “buy” rating and a $44.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $42.40.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new position in Dianthus Therapeutics in the fourth quarter worth $25,000. Citigroup Inc. acquired a new position in Dianthus Therapeutics in the third quarter valued at about $53,000. Dimensional Fund Advisors LP acquired a new position in Dianthus Therapeutics in the fourth quarter valued at about $153,000. Northern Trust Corp bought a new stake in shares of Dianthus Therapeutics in the fourth quarter worth about $159,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Dianthus Therapeutics in the third quarter worth about $303,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Down 1.6 %

The firm has a fifty day simple moving average of $25.81 and a 200-day simple moving average of $17.23.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. On average, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.